利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

85 条记录 (耗时 0.039 秒)

    PATHOLOGY BIOMARKER ASSAY
    22.
    发明公开
    PATHOLOGY BIOMARKER ASSAY 审中-公开

    公开(公告)号：EP3590959A3

    公开(公告)日：2020-04-08

    申请号：EP19188754.6

    申请日：2012-07-18

    申请人： Nordic Bioscience A/S

    发明人： VEIDAL, Sanne ,  KARSDAL, Morten Asser ,  LEEMING, Diana Julie ,  BARASCUK, Natasha ,  SKJOT-ARKIL, Helene ,  VASSILIADIS, Efstathios

    IPC分类号： C07K14/78 ,  G01N33/53 ,  G01N33/68 ,  C07K7/00

    摘要： Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a bioflui sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described.

    COLLAGEN IV NEO-EPITOPE FIBROSIS ASSAY
    23.
    发明公开
    COLLAGEN IV NEO-EPITOPE FIBROSIS ASSAY 审中-公开

    公开(公告)号：EP3578664A1

    公开(公告)日：2019-12-11

    申请号：EP19174151.1

    申请日：2010-03-29

    申请人： Nordic Bioscience A/S ,  Novartis AG

    发明人： VEIDAL, Sanne ,  KARSDAL, Morten ,  LEEMING, Diana Julie ,  BARASCUK MICHAELSEN, Natasha ,  SKJOT-ARKIL, Helene ,  SEGOVIA-SILVESTRE, Antonio ,  VASSILIADIS, Efstathios

    IPC分类号： C12Q1/00 ,  G01N33/68

    摘要： Methods of diagnosis or of quantitation of fibrosis comprising conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a bioflui sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising:
    contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope, and wherein said protein is collagen type III, collagen type I, collagen type IV, collagen type V, or collagen type VI, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein.

    CRP NEO-EPITOPE FIBROSIS ASSAY
    28.
    发明公开
    CRP NEO-EPITOPE FIBROSIS ASSAY 审中-公开
    CRP NEO-表位纤维化测定

    公开(公告)号：EP3173792A2

    公开(公告)日：2017-05-31

    申请号：EP16205956.2

    申请日：2010-03-29

    申请人： Nordic Bioscience A/S ,  Novartis AG

    发明人： VEIDAL, Sanne ,  KARSDAL, Morten ,  LEEMING, Diana Julie ,  BARASCUK MICHAELSEN, Natasha ,  SKJOT-ARKIL, Helene ,  SEGOVIA-SILVESTRE, Antonio ,  VASSILIADIS, Efstathios

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  C12Q1/37 ,  G01N2333/4737 ,  G01N2333/78 ,  G01N2800/085 ,  G01N2800/32 ,  G01N2800/50

    摘要： Methods of diagnosis or of quantitation of fibrosis comprising conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a bioflui sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising:
    contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and
    measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope, and wherein said protein is collagen type III, collagen type I, collagen type IV,
    collagen type V, or collagen type VI, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein.

    摘要翻译： 诊断或定量纤维化的方法包括进行免疫测定以测量天然存在于bioflui样品中的含有新表位的蛋白质片段，并且将所述患者中所述测量值在正常水平以上的升高与纤维化的存在或程度相关联。 所述免疫测定法通过包括以下步骤的方法进行：使天然存在于所述样品中的蛋白质片段与免疫学结合配偶体接触，所述免疫学结合配偶体与通过蛋白酶裂解蛋白质形成的新表位反应并测量肽片段与所述免疫学结合的结合程度 其中所述蛋白质是III型胶原蛋白，I型胶原蛋白，IV型胶原蛋白，V型胶原蛋白或VI型胶原蛋白，弹性蛋白，双糖链蛋白聚糖，核心蛋白聚糖，lumican，多功能蛋白聚糖，基底膜蛋白聚糖， neurocan，短裂解蛋白，纤维调节蛋白，serglycin，多配体聚糖，β聚糖，波形蛋白或C反应蛋白。